Results 211 to 220 of about 35,714,339 (381)

Treatment of Macroglobulinaemia [PDF]

BMJ, 1962
N, CONWAY, J M, WALKER
openaire   +4 more sources

Cognitive behavioural treatment of insomnia in individuals with persistent persecutory delusions: A pilot trial

, 2011
Elissa Myers, Helen Startup, Daniel Freeman   +2 more
openalex   +1 more source

Composition and aggregation of extracellular polymeric substances (EPS) in hyperhaline and municipal wastewater treatment plants [PDF]

, 2016
Jie Zeng, Junmin Gao, You‐Peng Chen, Peng Yan, Yang Dong, Yu Shen, Jinsong Guo, Ni Zeng, Peng Zhang   +8 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Pharmacist-Led Hepatitis C Diagnosis and Rapid Management-In Community (PHARM-C): Results From a Phase IV Nonblinded Randomised Controlled Trial. [PDF]

J Viral Hepat
Biondi MJ, Capraru CI, Harper B, Gill P, Dale CH, Nicolle J, Chung D, Boutrous M, Wilson AD, Lam V, Morkos D, Barber B, Usoro MA, Mendlowitz AB, Shah H, Fontaine G, Hansen B, Feld JJ.   +17 more
europepmc   +1 more source

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight

, 2017
Ilina Singh, Celia J. A. Morgan, Valerie H. Curran, David Nutt, Anne Katrin Schlag, Rupert McShane   +5 more
openalex   +2 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Medical Management of Polycystic Liver Disease: A Position Statement From the European Reference Network on Hepatological Diseases. [PDF]

Liver Int
Heinrich S, de Matos AMC, Colmenero J, Elsharkawy AM, Fraňková S, Halbritter J, Mrzljak A, Müller RU, Pereira R, Strnad P, Teemer CAJ, Verbeek J, Wronka KM, Nevens F, Taubert R, Drenth JPH, European Reference Network on Hepatological Liver Diseases (ERN RARE‐LIVER).   +16 more
europepmc   +1 more source

Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials [PDF]

, 2017
Noori Al-Waili, Hamza Al-Waili, Thia Al-Waili, Khelod Salom   +3 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source